Sobi to present clinical data on Gamifant® at Histiocyte Society 2026 in Rotterdam

Sobi will present new clinical data for Gamifant (emapalumab) in primary haemophagocytic lymphohistiocytosis (HLH) at the Histiocyte Society's 2026 annual meeting on September 26-29. The announcement signals continued clinical-development activity for the rare-disease therapy, but provides no efficacy, safety, regulatory, or financial results to assess material valuation impact.